| Project/Area Number |
17K16713
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Anesthesiology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
KANDA Megumi
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 神経障害性疼痛 / TNF-α / 遺伝子治療 / 活性酸素 |
|---|
| Outline of Final Research Achievements |
While effective antiretroviral treatment makes human immunodeficiency virus (HIV)-related death decreased dramatically,neuropathic pain becomes one of the most common complications in patients with HIV/acquired immunodeficiency syndrome (AIDS). The exact mechanisms of HIV-related neuropathic pain are not well understood yet, and no effective therapy is for HIV-pain. Evidence has shown that proinflammatory factors (e.g., tumor necrosis factor alpha(TNFα)) released from glia, are critical to contributing to chronic pain. Preclinical studies have demonstrated that non-replicating herpes simplex virus (HSV)-based vector expressing human enkephalin reduces inflammatory pain,neuropathic pain, or cancer pain in animal models. In this review, we describe recent advances in the use of HSVbased gene transfer for the treatment of HIV pain, with a special focus on the use of HSV-mediated soluble TNF receptor I (neutralizing TNFα in function) in HIV neuropathic pain model.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究の成果は、神経障害性疼痛に対する遺伝子治療の開発につながるものである。遺伝子治療の臨床応用が実現すれば、難治性疼痛に苦しむ患者のQOLを上昇させることができる。
また、現在使用されている麻薬性鎮痛薬の使用量を軽減させることが可能となる。
|
